Background: Medical students are under high pressure to perform academically and also face the impact of the COVID-19 pandemic, putting them at risk of developing burnout. Aims: This study aims to evaluate the prevalence and degree of burnout among medical students in Indonesia during 1 month of the COVID-19 pandemic. Methods: From April to May 2021, we conducted an online survey of Indonesian medical students to assess burnout (using Maslach Burnout Inventory-Student Survey, MBI-SS). Results: A total of 1,947 students from 27 universities participated in the study. About 35.5% had burnout, 41.7% with a moderate to high level of emotional exhaustion, 45% had moderate to high level of depersonalization and 66.7% had a low level of personal accomplishment. Conclusion: A total of 35.5% of medical students in our sample experienced burnout. We suggest further research to explore and identify factors related to these findings and the need for potential interventions at global and national level to enhance the well-being of medical students.
Prospective data of thirty-three consecutive patients with inoperable stage III NSCLC completed CRT with sequential Durvalumab (77%, 22 patients) or concurrent and sequential Nivolumab (33%, 11 patients) were analyzed. Different cut offs for PTV were evaluated for association with progression-free (PFS) survival. Results: All patients were treated with conventionally fractionated TRT; 93% to a total dose of at least 60 Gy (range: 60-63.6Gy). 97% of patients received two cycles of concurrent platinum-based chemotherapy. Median follow-up for the entire cohort was 19.9 (range: 6.0-42.4) months; median overall survival (OS) was not reached. Median Progression-free survival (PFS) was 22.8 (95% CI: 10.7-34.8) months. Patients with PTV ≥ 900ccm had a significantly shorter PFS (6.9 vs 22.8 months, p = 0.020) and extracranial metastasis free survival (eMFS) (8.1 months vs not reached, p = 0.026). Furthermore, patients with PTV ≥ 900ccm and stage IIIC disease (TNM 8 th Ed.) achieved a dismal median PFS of only 3.5 months (vs. 26.3 months p = 0.022). Conclusions: PTV has a significant impact on the PFS and eMFS after CRT combined with concurrent and/or sequential CPI in inoperable stage III NSCLC. Patients with PTV ≥ 900ccm had a significantly shorter PFS and eMFS.
months (HR:0.40, p = 0.008). Subgroup analysis found that the PFS benefit of PC was evident in most subgroups excepting patients with brain metastasis. The 1-year overall survival rate of PC and PM were 89.0% and 78.3%, respectively. The ORR were 61.7% and 46.9% (p = 0.040), respectively. Conclusions: In patients with previously untreated, PD-L1≥50%, advanced NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard platinum-based chemotherapy should be recommended as the preferred treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.